About: drug pricing

Health 07-11-2018

Greek minister: Effective health and pharma policy needs stronger EU Commission role

A number of member states want the European Commission’s competences in health and pharma policy to be upgraded in order to face more effectively the rising challenges in the field, Greek health minister Andreas Ksanthos told EURACTIV.com in an interview.
Health 10-10-2018

New drugs: how much are governments paying for innovation?

The European healthcare sector is divided over the “actual value” EU governments pay for the authorised and partly public-funded novel drugs, compared to medicines already on the market.
Health 10-07-2018

Investment in digital health and access to drugs at the core of Austrian Presidency

Austria’s EU Presidency will focus on “strong” investment in digital health as well as on regulatory issues when it comes to access to medicines, Dr Clemens Martin Auer told EURACTIV.com in an interview. Dr Clemens Martin Auer is the president of the...
Health 03-07-2018

EFPIA President: Next EU Commission should prioritise competitiveness in pharma innovation

The next European Commission should focus on the bloc’s role in the global context of innovation, as China is “decisive” about creating a reliable framework for intellectual property and connecting biotech start-ups and digital companies, EFPIA’s President Stefan Oschmann told EURACTIV.com in an interview.  
Health 14-06-2018

Expert: Drug remuneration based on outcome should include distributors

The adoption of an outcome-based approach regarding the remuneration of medicines should take into account the entire chain, including the distributors, René Jenny, President of the European Healthcare Distribution Association (GIRP), told EURACTIV.com.
Health 08-05-2018

Time to end fragmentation of EU healthcare, experts say

Experts are asking for a more collaborative approach in EU healthcare and greater involvement of the European Commission in order to face rising challenges and put patients at the core of decision-making.
Economy & Jobs 26-02-2018

Greek business chief: Novartis scandal must be dealt with quickly to avoid ‘social eruption’

The Novartis scandal in Greece exists and the people responsible for it should be dealt with quickly in order to avoid a “social eruption”, Greek business leader Konstantinos Michalos told EURACTIV.com in an interview.
Health 22-02-2018

Greek politicians face probe in pharma bribery scandal

The Greek parliament decided on 21 February to establish a special committee that will investigate the role of politicians in the alleged Novartis scandal, a case that analysts claim will shake up the country’s political system.
Health 16-02-2018

Greek judges call for calm over Novartis scandal

The Greek Union of Judges and Prosecutors called for “calmness and sobriety” on Friday (16 February), following a lawsuit by former Prime Minister Antonis Samaras against Premier Alexis Tsipras and Prosecutor of Corruption Eleni Touloupaki over the Novartis scandal.
Health 06-02-2018

Pharma scandal whips up political storm in Greek opposition ranks

A probe into illegal practices of Swiss drugmaker Novartis in Greece, involving thousands of state officials and doctors, has opened the Pandora’s Box in Greek politics as local media have named ten former bigwigs from opposition parties as being targeted by the investigation.
Health 01-02-2018

EU southern alliance on drug pricing expands

Slovenia joined the “Valletta Declaration”, an alliance of southern EU member states, which aims to explore strategies to jointly negotiate prices with the pharma industry, as well as Croatia with an observer status. 
Health 29-01-2018

Health expert: Europe should not put its dominant pharma innovation at risk

The European Union should not create an environment more favourable to generics compared to the innovative pharmaceuticals, as it risks weakening Europe’s overall global strength in pharmaceuticals and in research, Professor Adrian Towse told EURACTIV.com in an interview.
Health 08-12-2017

Drug pricing debate to take place in heated atmosphere

Following a Greek government request, the Employment, Social Policy, Health and Consumer Affairs Council (EPSCO) will discuss on Friday (8 December) a recent dispute between Athens and ROCHE, a Swiss multinational company, over the latter’s decision to withdraw a cancer drug from the market.
Health 07-12-2017

Celgene boss: Chronic diseases will bankrupt Europe if incentives are dropped

Alzheimers, diabetes, cancer and other non-communicable diseases will bankrupt Europe if we don’t keep the incentive frameworks alive and well, Mark Alles told EURACTIV.com in an interview.
Health 24-11-2017

Athens brings its dispute with pharma industry to the EU Council

The next EU Health Council on 8 December will discuss the “lack of drug availability in Greece”, amid mounting tensions between the leftist government in Athens and the pharmaceutical companies.
Health 02-11-2017

Pharmaceutical company gives free access to drug after clash with Greek government

Following a clash with the Greek government over its decision to withdraw a cancer drug from the market, ROCHE, a Swiss multinational company, ultimately decided to make the drug available to patients for free.
Health 31-10-2017

Greek health minister fumes at pharmaceutical company after drug withdrawal

The Greek ministry of health reacted strongly to the decision of a pharmaceutical company to withdraw a drug from the market for “viability” reasons, saying it will not accept any blackmail.
Health 30-10-2017

Pharmaceutical company withdraws oncology drug from Greek market

A multinational pharmaceutical company has decided to withdraw an innovative oncology medicine from the Greek market, claiming that its price has fallen more than 50% because of the government’s regulatory interventions in the pharma area, EURACTIV.com has learnt.
Health 25-10-2017

Greek government on collision course with pharmaceutical companies over innovative drugs

Several pharmaceutical companies in Greece have threatened to stop supplying the market with innovative drugs and said they could even withdraw existing drugs as a result of an obligatory “discount” imposed by the Greek government and applied retroactively.
Health 04-10-2017

Gastein boss: Drugs access is ‘sensitive’ and cannot be viewed in isolation

Accessibility of medicines is a sensitive issue that must not be examined in isolation. Policymakers, academics, business and patients must be part of the discussion as well as “innovation” because access would not get the focus it needs without it, according to Dorli Kahr-Gottlieb.
Health 16-05-2017

Commission opens first investigation into excessive drug pricing

The European Commission announced yesterday (15 May) that it opened a formal investigation into Aspen Pharma's pricing practices for cancer drugs.
Health 17-03-2017

Pharma boss: Some EU countries effectively delay market entry of generics

The harmonisation of different regulatory environments in the EU member states will help generic drugs enter the market, resulting in reduced prices for medicine and better patient access, Jacek Glinka told EURACTIV.com in an interview.